On Aug. 10, 2020, Omeros reported the results of a compassionate-use study evaluating narsoplimab, Omerosﾒ investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome. All patients initially required mechanical ventilation, and all recovered and survived with narsoplimab treatment. A manuscript detailing the results of the study was accepted for publication in the peer-reviewed journal Immunobiology.